Aminobisphosphonates: Reconsideration 25 years after their approval for the treatment of osteoporosis

Rogers, 2004, From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates, Calcif Tissue Int, 75, 451, 10.1007/s00223-004-0024-1 Rodan, 2004, Bone safety of long-term bisphosphonate treatment, Curr Med Res Opin, 20, 1291, 10.1185/030079904125004475 Duford, 2008, Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase, J Med Chem, 51, 2187, 10.1021/jm7015733 Nancollas, 2006, Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite, Bone, 38, 617, 10.1016/j.bone.2005.05.003 Ebetino, 2022, Bisphosphonates: the role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use, Bone, 156, 116289, 10.1016/j.bone.2021.116289 Reid, 2008, A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International, Int J Clin Pract, 62, 575, 10.1111/j.1742-1241.2008.01704.x Rosen, 2005, Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study, J Bone Miner Res, 20, 141, 10.1359/JBMR.040920 Roelofs, 2010, Fluorescent risedronate analogs reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo, J Bone Miner Res, 25, 606, 10.1359/jbmr.091009 Plotkin, 2008, Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo, J Bone Miner Res, 23, 1712, 10.1359/jbmr.080617 Corrado, 2017, Osteoblast as a target of antiosteoporotic treatment, Postgrad Med, 129, 858, 10.1080/00325481.2017.1362312 Bone, 2004, Ten years’ experience with alendronate for osteoporosis in postmenopausal women, N Engl J Med, 350, 1189, 10.1056/NEJMoa030897 Eastell, 2021, Treatment-related changes in bone turnover and fracture risk reduction in clinical trials of antiresorptive drugs: proportion of treatment effect explained, J Bone Miner Res, 36, 236, 10.1002/jbmr.4178 Liberman, 1995, Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group, N Engl J Med, 333, 1437, 10.1056/NEJM199511303332201 Black, 1996, Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group, Lancet, 348, 1535, 10.1016/S0140-6736(96)07088-2 Cummings, 1998, Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial, JAMA, 280, 2077, 10.1001/jama.280.24.2077 Black, 2000, Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group, J Clin Endocrinol Metab, 85, 4118, 10.1210/jcem.85.11.6953 Harris, 1999, Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group, JAMA, 282, 1344, 10.1001/jama.282.14.1344 Reginster, 2000, Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group, Osteoporos Int, 11, 83, 10.1007/s001980050010 McClung, 2001, Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group, N Engl J Med, 344, 333, 10.1056/NEJM200102013440503 Pazianas, 2013, Eliminating the need for fasting with oral administration of bisphosphonates, Ther Clin Risk Manag, 9, 395, 10.2147/TCRM.S52291 Chesnut, 2004, Oral ibandronate osteoporosis vertebral fracture trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis, J Bone Miner Res, 19, 1241, 10.1359/JBMR.040325 Miller, 2005, Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study, J Bone Miner Res, 20, 1315, 10.1359/JBMR.050313 Delmas, 2006, Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study, Arthritis Rheum, 54, 1838, 10.1002/art.21918 Black, 2007, Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis, N Eng J Med, 356, 1809, 10.1056/NEJMoa067312 Lyles, 2007, Zoledronic acid and clinical fractures and mortality after hip fracture, N Engl J Med, 357, 1799, 10.1056/NEJMoa074941 Reid, 2018, Fracture prevention with zoledronate in older women with osteopenia, N Engl J Med, 379, 2407, 10.1056/NEJMoa1808082 Barrionuevo, 2019, Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a Network Meta-Analysis, J Clin Endocrinol Metab, 104, 1623, 10.1210/jc.2019-00192 Sanderson, 2016, Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: a systematic review and network meta-analysis, Bone, 89, 52, 10.1016/j.bone.2016.05.013 Wang, 2017, The efficacy and safety of vertebral fracture prevention therapies in postmenopausal osteoporosis treatment, Bone Joint Res, 6, 452, 10.1302/2046-3758.67.BJR-2016-0292.R1 Tan, 2019, Comparative efficacy and safety of pharmacological interventions fior osteoporosis in postmenopausal women: a network meta-analysis (Chongqing. China), Menopause, 26, 929, 10.1097/GME.0000000000001321 Silverman, 2007, Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study, Osteoporos Int, 18, 25, 10.1007/s00198-006-0274-z Curtis, 2009, RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction, Osteoporos Int, 20, 973, 10.1007/s00198-008-0772-2 Thomasius, 2022, Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data análisis, Osteoporos Int, 33, 217, 10.1007/s00198-021-06108-w Black, 2020, Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates, N Engl J Med, 383, 743, 10.1056/NEJMoa1916525 Chiu, 2018, The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects, PLoS One, 13, 10.1371/journal.pone.0196419 On, 2021, Various therapeutic methods for the treatment of medication-related osteonecrosis of the jaw (MRONJ) and their limitations: a narrative review on new molecular and cellular therapeutic approaches, Antioxidants, 10, 680, 10.3390/antiox10050680 Reid, 2020, Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women, J Bone Miner Res, 35, 20, 10.1002/jbmr.3860 Eiken, 2016, Treatment of osteoporosis after alendronate or risedronate, Osteoporos Int, 27, 1, 10.1007/s00198-015-3334-4 Geusens, 2018, Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial, J Bone Miner Res, 33, 783, 10.1002/jbmr.3384 Langdahl, 2017, Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial, Lancet, 390, 1585, 10.1016/S0140-6736(17)31613-6 Lindsay, 2004, Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis, Ann Int Med, 164, 2024, 10.1001/archinte.164.18.2024 Bone, 2018, ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis, J Clin Endocrinol Metab, 103, 2949, 10.1210/jc.2018-00163 Saag, 2017, Romosozumab or alendronate for fracture prevention in women with osteoporosis, N Engl J Med, 377, 1417, 10.1056/NEJMoa1708322 Black, 2003, The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis, N Engl J Med, 349, 1207, 10.1056/NEJMoa031975 Cosman, 2011, Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis, J Bone Miner Res, 26, 503, 10.1002/jbmr.238 Finkelstein, 2003, The effects of parathyroid hormone, alendronate, or both in men with osteoporosis, N Engl J Med, 349, 1216, 10.1056/NEJMoa035725 Cosman, 2009, Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent, J Clin Endocrinol Metab, 94, 3772, 10.1210/jc.2008-2719 Black, 2006, Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial, JAMA, 296, 2927, 10.1001/jama.296.24.2927 Black, 2012, The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT), J Bone Miner Res, 27, 243, 10.1002/jbmr.1494 Schwartz, 2010, Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial, J Bone Miner Res, 25, 976, 10.1002/jbmr.11 Adler, 2016, Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research, J Bone Miner Res, 31, 16, 10.1002/jbmr.2708 Compston, 2019, Osteoporosis, Lancet, 393, 364, 10.1016/S0140-6736(18)32112-3 Black, 2020, Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials, Lancet Diabetes Endocrinol, 8, 672, 10.1016/S2213-8587(20)30159-5 Black, 2015, The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT), J Bone Miner Res, 30, 934, 10.1002/jbmr.2442 Curtis, 2008, Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday, Osteoporos Int, 19, 1613, 10.1007/s00198-008-0604-4 Mignot, 2017, Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk, Osteoporos Int, 28, 3431, 10.1007/s00198-017-4215-9 Adams, 2018, Bisphosphonate drug holiday and fracture risk: a population-based cohort study, J Bone Miner Res, 33, 1252, 10.1002/jbmr.3420 Pfeilschifter, 2020, Bisphosphonate drug holidays: risk of fractures and mortality in a prospective cohort study, Bone, 138, 10.1016/j.bone.2020.115431 Riancho, 2021, Guías de práctica clínica en la osteoporosis posmenopáusica, glucocorticoidea y del varón (actualización 2021). Sociedad Española de Investigación Ósea y del Metabolismo Mineral (SEIOMM), Rev Clin Esp Cummings, 2009, Denosumab for prevention of fractures in postmenopausal women with osteoporosis, N Eng J Med, 361, 756, 10.1056/NEJMoa0809493